The Post Intensive Care Syndrome Follow-up and Management Study: the ICU Recovery Answers Project
Launched by CORPORACION PARC TAULI · Jul 10, 2024
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult (≥18 years old) critically ill patients admitted to the ICU with or without need of invasive mechanical ventilation (IMV).
- Exclusion Criteria:
- • Non-authorization of the relatives and/or patient to inclusion in the study; neurocritical ICU patients.
- • Severe neurological pathology (including dementia or focal brain damage with functional and cognitive impairment) prior to admission to the ICU.
- • Severe psychiatric pathology (schizophrenia, bipolar disorder, major depressive disorder)
- • Intellectual disability (IQ \<80).
- • Patients who develop secondary complications (infections, stroke, TBI or any non-transient acquired brain damage) after ICU discharge, that may compromise the results of the emotional and neuropsychological evaluation during the recovery phase
- • Moderate-severe cognitive impairment (Short-IQCODE \>85) that impair ICU patients an independent participation in the telematic follow up and accompaniment program
- • Readmission to ICU within 12 months after discharge from ICU
- • Idiomatic barrier (non spanish and/or catalan speaker)
- • Patients with life expectancy \<1 year or not subsidiaries of active treatment measures.
About Corporacion Parc Tauli
Corporación Parc Taulí is a leading healthcare organization based in Sabadell, Spain, known for its commitment to advancing medical research and clinical excellence. With a focus on innovative healthcare solutions, the organization integrates cutting-edge technology and multidisciplinary collaboration to enhance patient outcomes. As a sponsor of clinical trials, Corporación Parc Taulí emphasizes ethical practices, rigorous scientific methodologies, and robust data management to contribute to the development of new therapies and improve healthcare standards. Their dedication to research and patient care positions them as a vital player in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sabadell, Barcelona, Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported